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Objectives: Thyroid cancer is a rare and heterogeneous disease. While many 
patients have a good prognosis, a subset of 5-20% experience recurrence and pro-
gressive disease. Resource use in patients with thyroid cancer, and specific subtypes 
such as medullary thyroid cancer (MTC) and differentiated thyroid cancer (DTC), are 
not well characteristised; therefore, the study evaluated characteristics, health care 
utilization and costs in a commercially insured US population. MethOds: A retro-
spective observational cohort analysis, using the HealthCore Integrated Research 
Environment (HIRE) for the period 01/1/2006 through 8/31/2012, was conducted. 
Cases were defined by at least 2 diagnoses of thyroid cancer within 60 days, and 
algorithms were developed to further sub-classify patients into histologic groups. 
Baseline (defined as 12 months prior to first diagnosis) and post-diagnosis charac-
teristics and costs were calculated. Results: 6,823 thyroid cancer patients were 
identified, including 280 MTC, 3,238 DTC. Mean age was 49.2 years and less than 
1% were children; 76% of patients were female. At baseline, the most common 
comorbidities were infection (45%), hypertension (33%), hypothyroidism (32%) and 
chronic fatigue (21%). Resource use and medication utilization was substantially 
different between subgroups. 63% of all patients had at least one post-diagnosis 
hospitalisation, which was higher in DTC (77%) and MTC (70%) than uncatego-
rised patients. Around 30% of all patients had ≥ 1 emergency department visit. 
DTC patients filled significantly more thyroid specific medications. Patients with 
advanced disease(N= 2,399) had more comorbidities, greater health care utilization 
and costs. Total health care costs per patients year across all patients was $17K, 
and were significantly higher in patients with MTC ( $24K), and those with any 
advanced thyroid cancer ($46K). cOnclusiOns: Thyroid cancer is a costly and 
resource intensive disease. While MTC patients incurred greater total health care 
costs, driven largely by hospitalizations and outpatient visits, advanced disease was 
associated with the highest resource utilization and costs.
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Objectives: Assess the annual number of patients with MCL who relapse or are 
refractory to first line therapy in selected European countries. MethOds: A sys-
tematic literature review, aiming to identify and summarize all evidence related 
to outcomes of current treatment options for MCL was conducted. A comprehen-
sive literature search of two databases (PUBMED and Cochrane) from 2005-2014, 
and proceedings from major hematology/oncology conferences was undertaken. 
In addition, data from various cancer registries, surveillance and cohort studies 
were analyzed. Incidence and prevalence of MCL was calculated and patient out-
comes (e.g. overall response rate [ORR] and progression-free survival [PFS]) were 
summarized. Data analysis was stratified for subpopulations by age, ECOG per-
formance status and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden and 
the UK). Results: The proportion of MCL as a subtype of NHL ranges from 2.0% to 
7.1%. Minimum and maximum estimates of the newly diagnosed total patients with 
MCL in Europe range from 3,219 to 6,177 patients (0.6 – 1.2 per 100,000) in 2012, and 
the estimated prevalence ranges from 9,014 to 17,296 (1.8 – 3.4 per 100,000). Overall 
response (OR) rates after first line immunochemotherapy in MCL patients ranges 
from 63% to 97%, complete response (CR) rates range from 15% to 96%. Progression-
free survival (PFS) ranges from 16 months to 83 months. Based on evidence derived 
from this review, the steady-state prevalence of patients with relapsed or refractory 
MCL ranges from 1,778 – 8,799 patients annually, requiring second line treatment in 
the countries under study. cOnclusiOns: Despite improved treatment alternatives 
and improved outcomes in patients with MCL, remission duration is still short and 
the proportion of patients needing 2nd line and subsequent lines of therapy is high.
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Objectives: To determine whether a new cancer diagnosis affects drug therapy for 
diabetes among Medicare beneficiaries. MethOds: We identified diabetes patients 
from a 5% random sample of Medicare beneficiaries enrolled in Medicare Part D in 
2007 and 2008. We then identified the subset with newly diagnosed cancer between 
January and December 2007 (N= 4,457). The comparison group represented ben-
eficiaries with diabetes who had no evidence of cancer during the study period 
(N= 29,187). Use and adherence with oral hypoglycemic agents, RAAS-inhibitors, and 
statins were tracked during 6-month periods prior to and after cancer diagnosis and 
a matching index date for non-cancer controls. Monthly adherence was measured 
by the percentage of days covered (PDC). We estimated difference-in-difference-in-
difference (DDD) equations to assess the independent impact of cancer diagnosis 
and poor prognosis (died in month 7 to 12 after index date) on PDC controlling for 
individual characteristics. Results: We found that adherence declined between 
the pre-index and post-index periods for all drug classes with the sharpest drop 
evident among cancer patients who subsequently died in month 7 to 12. Depending 
on drug class, a cancer diagnosis reduced PDC by 4.7% to 6.1% among survivors and 
by 7.6% to 16.4% for decedents. Among non-cancer controls, the declines ranged 
between 1.5% and 3.2% (survivors) and between 5.7% and 9.1% (decedents). Similarly, 
Objectives: Major discordance for the initial diagnosis could induce a strong 
impact on therapeutic strategies and costs. To deal with this problem, the cost of dis-
cordant diagnoses was assessed in sarcoma patients treated in France. MethOds: 
This multicenter analysis was performed retrospectively using prospective-imple-
mented databases. Inclusion criteria were sarcoma patients with a discordant 
diagnosis after histological review performed within the RRePS network in 2010. 
Diagnoses were considered discordant when the final diagnosis was not categorized 
in the same way as the initial finding, as defined by the World Health Organization 
Classification. Therapeutic strategies related to the diagnosis were based on patient 
and disease characteristics and using national or international guidelines when 
available. All the strategies were defined by the authors. Related costs were assessed 
for initial diagnosis inducing specific managements and the management expected 
with the restored diagnosis after second opinion by pathologist expert. Costs were 
assessed according to the French National Health Insurance (NHI) perspective. The 
time horizon included initial treatments and a one year follow-up period. All costs 
were expressed in Euros 2013. Uncertainty was assessed by probabilistic sensitivity 
analysis. Results: Out of the 2,425 patients that underwent histological review, 
341 patients had a major discordance in their diagnosis (14.1%). Ten patients were 
excluded due to missing data. The costs of the therapeutic strategies for the initial 
diagnosis reached € 2,186,816 for the NHI. More precisely, costs [95% CI] reached: 
€ 696,452 [€ 535,745–€ 857,159] for gastrointestinal stromal tumors (GIST) (n= 35) 
confounded with non-GIST; € 695,755 [€ 547,822–€ 843,688] for sarcoma (n= 74) con-
founded with non-sarcoma malignant tumors; € 533,987 [€ 450,333–€ 617,641] for sar-
coma confounded with benign tumors (n= 117). cOnclusiOns: This study revealed 
the high cost of the therapeutic strategies resulting from misdiagnosis. Based on 
the publication of Lapeyrere, where the cost per histological review reached € 228, 
histological reviews would result in a cost saving of € 1,633,916 in 2010.
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Objectives: Assess the annual number of patients with chronic lymphocytic leu-
kemia (CLL)/small cell lymphocytic leukemia (SLL) who relapse or are refractory to 
first line therapy in selected European countries. MethOds: A systematic litera-
ture review, aiming to identify and summarize all evidence related to outcomes of 
current treatment options for CLL/SLL was conducted. A comprehensive literature 
search of two databases (PUBMED and Cochrane) from 2005-2014, and proceed-
ings from major hematology/oncology conferences was undertaken. In addition, 
data from various cancer registries, surveillance and cohort studies were analyzed. 
Incidence and prevalence of CLL/SLL was calculated and patient outcomes (e.g. 
overall response rate [ORR] and progression-free survival [PFS]) were summarized. 
Data analysis was stratified for subpopulations by age, ECOG performance status, 
presence of del17p and first-line treatment options available in the countries under 
study (Belgium, France, Germany, Italy, The Netherlands, Poland, Spain, Sweden 
and the UK). Results: The incidence of CLL/SLL ranges from 4.9 to 6.9 per 100,000 
in the countries under study. The estimated number of newly diagnosed patients 
each year with CLL/SLL in Europe ranges from 19,383 to 26,411. ORR after first line 
chemo-immunotherapy ranged from 63% to 95%, with complete response rates 
ranging from 5% to 47%. PFS rates ranged from 19 to 80 months. Based on evidence 
derived from this review, the steady-state prevalence of patients with relapsed or 
refractory CLL/SLL resulted in 9,174 to 19,579 patients annually, requiring second 
line treatment in the countries under study. cOnclusiOns: CLL/SLL represents 
the largest adult leukemia in the western world. This systematic literature review 
identified the significant number of patients failing first-line therapy with relapsed 
or refractory disease. Despite the improved response rates achieved in the last dec-
ade, duration of response varies, with some patients having short durations only. 
Therefore, further improvement in treatment options is required.
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Objectives: Prostate-specific antigen (PSA) monitoring following a diagnosis of 
prostate cancer remains controversial. We sought to describe results and pre-
dictors of PSA monitoring among non-metastatic prostate cancer patients with 
employer sponsored health insurance. MethOds: Male patients with ≥ 2 medi-
cal claims with a diagnosis of prostate cancer (ICD-9-CM code 185.00) between 
1/1/2008-4/30/2013 (index date) were evaluated in Truven Health MarketScan 
Treatment Pathways 3.0. Included patients had ≥ 6 mo continuous enrollment 
prior to and ≥ 24 mo of continuous enrollment following their index date and 
no diagnosis of metastatic cancer anytime during the study period. Receipt of 
PSA laboratory tests following cancer diagnosis was evaluated in the follow-up 
period. Results: In total, 7,893 men met the inclusion criteria. 6,558 (83%) had 
a PSA test post-index and 69% of them had a second PSA. Mean days from index 
to first and second PSA were 372 and 220 days, respectively. Mean age was 59 
years among those with a PSA test and 72 years among those without. Of the 
2,245 patients with an available test result, 85% had normal PSA scores (77% 0 to 
< 2 ng/mL; 8% 2 to < 4 ng/mL), while 4.4% were ≥ 10 ng/mL. PSA was normal for 
89% (81% 0 to < 2 ng/mL; 8% 2 to < 4 ng/mL) with a 2nd PSA, while 3% were ≥ 10 
ng/mL. Men without a PSA test were more likely to have comorbid hypertension 
(74% vs. 20%), hyperlipidemia (60% vs. 20%), and diabetes (35% vs. 9%) than those 
with a test. cOnclusiOns: The majority of men had at least 1 PSA test within 
the first year following their diagnosis, and the majority of those results were in 
the normal range. Monitoring appears to be more common among healthier men. 
Future research should explore whether monitoring results in better outcomes.
